November 30, 2025Cell & BioscienceOpen Access

KDM6B inhibition enhances chemotherapeutic response in small cell lung cancer via epigenetic regulation of apoptosis and ferroptosis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Inhibition of KDM6B improves antitumor efficacy of chemotherapy in small cell lung cancer, indicating it may overcome chemoresistance.

KDM6B inhibition improves apoptosis and ferroptosis in small cell lung cancer.
In vivo experiments showed enhanced antitumor efficacy with Gskj1 during chemotherapy in SCLC.
Epigenetic regulation targeting KDM6B suggests a novel approach to overcome chemoresistance.
These findings highlight the potential of combining KDM6B inhibitors with standard chemotherapy.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark